<DOC>
	<DOCNO>NCT01960348</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy patisiran ( ALN-TTR02 ) patient transthyretin ( TTR ) mediate amyloidosis</brief_summary>
	<brief_title>APOLLO : The Study Investigational Drug , Patisiran ( ALN-TTR02 ) , Treatment Transthyretin ( TTR ) -Mediated Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<mesh_term>Amyloidosis , Familial</mesh_term>
	<criteria>Male female 18 85 year age ( inclusive ) ; Have diagnosis FAP Neuropathy Impairment Score requirement 5130 Meet Karnofsky performance status requirement Have adequate complete blood count liver function test Have adequate cardiac function Have negative serology hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Had prior liver transplant plan undergo liver transplant study period ; Has untreated hypo hyperthyroidism ; Has know human immunodeficiency virus ( HIV ) infection ; Had malignancy within 2 year , except basal squamous cell carcinoma skin carcinoma situ cervix successfully treat ; Recently receive investigational agent device Is currently take diflunisal , tafamidis , doxycycline , tauroursodeoxycholic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>FAP</keyword>
	<keyword>Familial Amyloid Polyneuropathy</keyword>
	<keyword>TTR</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>Amyloidosis</keyword>
</DOC>